Induction of Tc1 response and enhanced cytotoxic T lymphocyte activity in mice by dendritic cells transduced with adenovirus expressing HBsAg

Clinical Immunology

Volumn 119, Issue 3, 2006, Pages 280-290

  Huang, Yin ^a,b   Chen, Zhi ^a   Jia, Hongyu ^a   Wu, Wei ^a   Zhong, Shigen ^b   Zhou, Cheng ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

Cytotoxic T lymphocytes; Dendritic cells; Hepatitis B surface antigen; Hepatitis B virus; Interferon gamma; Interleukin 4; Recombinant adenovirus; Therapeutic vaccine; Transgenic mice

Indexed keywords

ADENOVIRUS VECTOR; DENDRITIC CELL VACCINE; DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; PLASMID DNA; RECOMBINANT HEPATITIS B VACCINE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; DRUG PULSE THERAPY; FEMALE; GENETIC ENGINEERING; HEPATITIS B; HEPATITIS B VIRUS; IMMUNIZATION; IMMUNOSTIMULATION; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TRANSGENIC MOUSE; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; DENDRITIC CELLS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; IMMUNIZATION; INTERFERON TYPE II; INTERLEUKIN-4; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; VACCINES, DNA;

EID: 33646425837     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.01.015     Document Type: Article

References (52)

1. Lai C.L., Ratziu V., Yuen M.F., and Poynard T. Viral hepatitis B. Lancet 362 (2003) 2089-2094
2. Raney A.K., Hamatake R.K., and Hong Z. Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin. Investig. Drugs 12 (2003) 1281-1295
3. Rivkin A.M. Adefovir dipivoxil in the treatment of chronic hepatitis B. Ann. Pharmacother. 38 (2004) 625-633
4. Sprengers D., and Janssen H.L. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam. Clin. Pharmacol. 19 (2005) 17-26
5. Chisari F.V., and Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13 (1995) 29-60
6. Rehermann B., Pasquinelli C., Mosier S.M., and Chisari F.V. Hepatitis B virus (HBV) sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J. Clin. Invest. 96 (1995) 1527-1534
7. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., and Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4 (1996) 25-36
8. Guidotti L.G., Ando K., Hobbs M.V., Ishikawa T., Runkel L., Schreiber R.D., and Chisari F.V. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3764-3768
9. Akbar S.M., Furukawa S., Horiike N., and Onji M. Vaccine therapy for hepatitis B virus carrier. Curr. Drug Targets Infect. Disord. 4 (2004) 93-101
10. Akbar S.M., Furukawa S., Hasebe A., Horiike N., Michitaka K., and Onji M. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrier. Int. J. Mol. Med. 14 (2004) 295-299
11. Shimizu Y., Guidotti L.G., Fowler P., and Chisari F.V. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J. Immunol. 161 (1998) 4520-4529
12. Chen M., Li Y.G., Zhang D.Z., Wang Z.Y., Zeng W.Q., Shi X.F., Guo Y., Guo S.H., and Ren H. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J. Gastroenterol. 11 (2005) 1806-1808
13. Banchereau J., Schuler-Thurner B., Palucka A.K., and Schuler G. Dendritic cells as vectors for therapy. Cell 106 (2001) 271-274
14. Akbar S.M., Horiike N., Onji M., and Hino O. Dendritic cells and chronic hepatitis virus carriers. Intervirology 44 (2001) 199-208
15. Guermonprez P., Valladeau J., Zitvogel L., Thery C., and Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20 (2002) 621-667
16. Kakimi K., Isogawa M., Chung J., Sette A., and Chisari F.V. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J. Virol. 76 (2002) 8609-8620
17. Wan Y., Bramson J., Carter R., Graham F., and Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8 (1997) 1355-1363
18. Hiasa Y., Horiike N., Akbar S.M., Saito I., Miyamura T., Matsuura Y., and Onji M. Low stimulatory capacity of lymphoid dendritic cells expressing hepatitis C virus genes. Biochem. Biophys. Res. Commun. 249 (1998) 90-95
19. Matsui M., Moriya O., Abdel-Aziz N., Matsuura Y., Miyamura T., and Akatsuka T. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells transduced with replication-defective recombinant adenovirus. Vaccine 21 (2002) 211-220
20. Liu G., Xiong Y., Wang H., Jia Y., Zhou J., Pan F., and Zhang Y. Establishment of high level expression HBV transgenic BALB/c mice and its genetic and expressive stability. Chin. J. Vet. Sci. 23 (2003) 580-582
21. Huang Y., Chen Z., Zhou C., Yao H., Li M., and Xu C. The modulation of thymosin alpha 1 in the maturation, differentiation and function of murine bone marrow-derived dendritic cells in the absence or presence of tumor necrosis factor-alpha. Int. Immunopharmacol. 4 (2004) 539-546
22. Matsui M., Moots R.J., Warburton R.J., Peace-Brewer A.L., Tussey L.G., Quinn D.G., McMichael A.J., and Frelinger J.A. Genetic evidence for difference between intracellular and extracellular peptides in influenza A matrix peptide-specific CTL recognition. J. Immunol. 154 (1995) 1088-1096
23. Nagayama Y., Kita-Furuyama M., Ando T., Nakao K., Mizuguchi H., Hayakawa T., Eguchi K., and Niwa M. A novel murine model of Graves' hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J. Immunol. 168 (2002) 2789-2794
24. Ishikawa T., Kono D., Chung J., Fowler P., Theofilopoulos A., Kakumu S., and Chisari F.V. Polyclonality and multispecificity of the CTL response to a single viral epitope. J. Immunol. 161 (1998) 5842-5850
25. Varga S.M., and Welsh R.M. High frequency of virus-specific interleukin-2-producing CD4(+) T cells and Th1 dominance during lymphocytic choriomeningitis virus infection. J. Virol. 74 (2000) 4429-4432
26. Chen Z., Dehm S., Bonham K., Kamencic H., Juurlink B., Zhang X., Gordon J.R., and Xiang J. DNA array and biological characterization of the impact of the maturation status of murine dendritic cells on their phenotype and antitumor vaccination efficacy. Cell. Immunol. 214 (2001) 60-71
27. Chamoto K., Kosaka A., Tsuji T., Matsuzaki J., Sato T., Takeshima T., Iwakabe K., Togashi Y., Koda T., and Nishimura T. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci. 94 (2003) 924-928
28. Zheng B.J., Zhou J., Qu D., Siu K.L., Lam T.W., Lo H.Y., Lee S.S., and Wen Y.M. Selective functional deficit in dendritic cell-T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J. Viral Hepat. 11 (2004) 217-224
29. Arima S., Akbar S.M., Michitaka K., Horiike N., Nuriya H., Kohara M., and Onji M. Impaired function of antigen-presenting dendritic cells in patients with chronic hepatitis B: localization of HBV DNA and HBV RNA in blood DC by in situ hybridization. Int. J. Mol. Med. 11 (2003) 169-174
30. Van Der Molen R.G., Sprengers D., Binda R.S., De Jong E.C., Niesters H.G., Kusters J.G., Kwekkeboom J., and Janssen H.L. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 40 (2004) 738-746
31. Wang F.S., Xing L.H., Liu M.X., Zhu C.L., Liu H.G., Wang H.F., and Lei Z.Y. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J. Gastroenterol. 7 (2001) 537-541
32. Fazle Akbar S.M., Furukawa S., Onji M., Murata Y., Niya T., Kanno S., Murakami H., and Horiike N. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol. Res. 29 (2004) 136-141
33. Zhang X., Gordon J.R., and Xiang J. Advances in dendritic cell-based vaccine of cancer. Cancer Biother. Radiopharm. 17 (2002) 601-619
34. Nishimura N., Nishioka Y., Shinohara T., and Sone S. Enhanced efficiency by centrifugal manipulation of adenovirus-mediated interleukin 12 gene transduction into human monocyte-derived dendritic cells. Hum. Gene Ther. 12 (2001) 333-346
35. Herrera O.B., Brett S., and Lechler R.I. Infection of murine bone marrow-derived dendritic cells with recombinant adenovirus vectors leads to presentation of encoded antigen by both MHC class I and class II molecules-potential benefits in vaccine design. Vaccine 21 (2002) 231-242
36. Liu Y., Huang H., Chen Z., Zong L., and Xiang J. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. J. Gene Med. 5 (2003) 668-680
37. Dobrzanski M.J., Reome J.B., and Dutton R.W. Therapeutic effect of tumor-reactive type 1 and type 2 CD8+ T cell subpopulations in established pulmonary metastases. J. Immunol. 162 (1999) 6671-6680
38. Dobrzanski M.J., Reome J.B., and Dutton R.W. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J. Immunol. 164 (2000) 916-925
39. Dobrzanski M.J., Reome J.B., and Dutton R.W. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection. J. Immunol. 167 (2001) 424-434
40. Chamoto K., Kosaka A., Tsuji T., Matsuzaki J., Sato T., Takeshima T., Lwakabe K., Togashi Y., Koda T., and Nishimura T. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy. Cancer Sci. 94 (2003) 924-928
41. Michel M.L., Davis H.L., Schleef M., Mancini M., and Tiollais P. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 5307-5311
42. Mancini M., Hadchouel M., Davis H.L., Whalen R.G., Tiollais P., and Michel M.L. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 12496-12501
43. You Z., Huang X., Hester J., Toh H.C., and Chen S.Y. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res. 61 (2001) 3704-3711
44. Restifo N.P., Bacik I., Irvine K.R., Yewdell J.W., McCabe B.J., Anderson R.W., Eisenlohr L.C., Rosenberg S.A., and Bennink J.R. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol. 154 (1995) 4414-4422
45. Miller G., Lahrs S., Pillarisetty V.G., Shah A.B., and DeMatteo R.P. Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Res. 62 (2002) 5260-5266
46. Gamvrellis A., Leong D., Hanley J.C., Xiang S.D., Mottram P., and Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell Biol. 82 (2004) 506-516
47. Tuettenberg A., Jonuleit H., Tuting T., Bruck J., Knop J., and Enk A.H. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy. Gene Ther. 10 (2003) 243-250
48. Peng S., Kim T.W., Lee J.H., Yang M., He L., Hung C.F., and Wu T.C. Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life. Hum. Gene Ther. 16 (2005) 584-593
49. Kim T.M., Hung C.F., Ling M., Juang J., He L., Hardwick J.M., Kumar S., and Wu T.C. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J. Clin. Invest. 112 (2003) 109-117
50. Ochsenbein A.F., Sierro S., Odermatt B., Pericin M., Karrer U., Hermans J., Hemmi S., Hengartner H., and Zinkernagel R.M. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411 (2001) 1058-1064
51. Zinkernagel R.M. On cross-priming of MHC class I-specific CTL: rule or exception?. Eur. J. Immunol. 32 (2002) 2385-2392
52. Wolkers M.C., Brouwenstijn N., Bakker A.H., Toebes M., and Schumacher T.N.M. Antigen bias in T cell cross-priming. Science 304 (2004) 1314-1317